Vycor Medical Reports 2025 Financial Growth Driven by International Expansion and Clinical Validation

Vycor Medical, Inc. announced financial results for the year ended December 31, 2025, reporting revenue of $1,863,400, representing a 17% increase over 2024. The company's Vycor Medical division, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, generated revenue of $1,796,070, an 18% increase driven primarily by international market growth. Operating profit for 2025 was $33,900, a significant improvement from an operating loss of $(9,145) in 2024, while non-GAAP operating profit reached $145,881 compared to $81,548 in the previous year.

The financial performance reflects the increasing clinical validation of Vycor's technologies. During 2025, seven new peer-reviewed studies were published on the ViewSite Brain Access System, bringing the total published peer-reviewed clinical papers to 50, with an additional 14 other clinical papers. These studies, published internationally including in the US, UK, Japan, and Mexico, highlight the clinical advantages of VBAS regarding reduced brain tissue damage, improved patient outcomes, and reduced hospital stay. The company's growing clinical evidence base supports its market expansion efforts, as detailed in their corporate information available at https://www.vycormedical.com.

For the NovaVision division, which offers therapy programs for visual disorders after stroke or brain injury, a significant clinical study on the NeuroEyeCoach program was published in 2025. The study compared home-based versus clinic-based use and concluded that both settings showed meaningful improvements with no significant differences in activities of daily living improvements. This validation of remote accessibility aligns with global healthcare trends toward digital home-based therapies and represents an important development for the company's therapeutic offerings. More information about NovaVision's approach can be found at https://www.novavision.com.

Gross profit for 2025 was $1,498,295, an 11% increase over 2024, though the gross margin decreased to 83% from 89% due to validation, shipping, higher manufacturing costs of new production, and a higher international sales mix. The NovaVision division, which remains in development, generated revenues of $67,330 for the year ended December 31, 2025, a decrease of 8% from 2024, but maintained a gross margin of 93%. The company reported non-GAAP cash operating expenses of $1,415,226 compared to $1,340,967 in 2024.

On a GAAP basis, the company reported operating expenses of $1,527,207, a net loss of $396,796, and a loss of $0.01 per share for 2025. These GAAP figures include non-cash depreciation of purchased assets ($63,143) and non-cash stock compensation charges ($48,838). The company provides non-GAAP financial measures excluding these charges to present what management considers a clearer view of continuing operations. The reconciliation between GAAP and non-GAAP results shows non-GAAP operating expenses of $1,415,226, non-GAAP operating profit of $145,881, and non-GAAP net loss of $284,815 or $0.01 per share for 2025.

The company's international growth strategy appears to be yielding results, with most revenue increases coming from international markets, though sales growth continued in the US. The combination of financial improvement and expanding clinical validation across both business units suggests Vycor Medical is strengthening its position in the medical technology sector. The ViewSite Brain Access System's clinical advantages and NovaVision's validation for remote therapy delivery address important healthcare needs, potentially creating sustainable growth opportunities as healthcare systems worldwide increasingly adopt minimally invasive surgical solutions and digital therapeutic approaches.